Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MITF | O75030 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | RORA | P35398 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495415 | 0.94 | TP53 (0.45) | L3MBTL1TDP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10764271 | 0.92 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL11613395 | 0.92 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL8778695 | 0.92 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL12096492 | 0.92 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL10767578 | 0.92 | ALDH1A1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| Hydrochloric Acid SCHEMBL1933284 | 0.91 | ALDH1A1 (0.46) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL174910 | 0.88 | NPC1 (0.49) | L3MBTL1TDP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9394796 | 0.87 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL9752675 | 0.87 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9ASMN1; SMN2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897439-A | Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| CN-117897440-A | Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| WO-2023033605-A1 | METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| CN-117897439-A | Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | disclosed |
| EP-3957603-A1 | HIGH-SILICA Y MOLECULAR SIEVE HAVING FAU TOPOLOGY AND PREPARATION METHOD THEREFOR | Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CN) | 2022-02-23 | — | — | EP | disclosed |
| WO-2021183758-A1 | IMMUNOMODULATING UREA AZALIDES | ZOETIS SERVICES LLC (US) | 2021-09-16 | — | — | WO | disclosed |
| WO-2020199191-A1 | LONG-LASTING PHOSPHOR MATERIAL | 复旦大学 | 2020-10-08 | — | — | WO | disclosed |
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| CN-100575345-C | 2 type Cannabined receptors are had in conjunction with active Pyridione derivatives | SHIONOGI & CO | 2009-12-30 | — | — | CN | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090099224-A1 | C7- substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20040099603-A1 | Method for separating a phase transfer catalyst by means of a membrane | MEMBRANE EXTRACTION TECHNOLOGY LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| CN-1492856-A | Pyridone derivative having affinity for cannabinoid 2-type receptor | ��Ұ����ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| WO-2002041978-A1 | METHOD FOR SEPARATING A PHASE TRANSFER CATALYST BY MEANS OF A MEMBRANE | MEMBRANE EXTRACTION TECHNOLOGY LIMITED (GB) | 2002-05-30 | — | — | WO | disclosed |
| EP-0259048-A2 | Chemical compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | BMP1, BMP4, BMP2 | L3MBTL1 826/4885TDP1 4207/4885NPC1 3037/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | L3MBTL1 1827/4885TDP1 1914/4885NPC1 4616/4885 |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | L3MBTL1 826/4885TDP1 4207/4885NPC1 3037/4885 |
| US-20090099224-A1 | C7- substituted camptothecin analogs | ABCB1, ABCC1, ABCG2 | L3MBTL1 1295/4885TDP1 1036/4885NPC1 673/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | L3MBTL1 2853/4885TDP1 2672/4885NPC1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.